Thomas Plyler
Primary Care · Myrtle Beach, SCNPI 1710608963
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,272, more than ten times the $94 reported in 2022.
Across 215 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$563
- Novo Nordisk$450
- AstraZeneca$232
- Sanofi-aventis U.S. LLC$193
- Pfizer$181
- Dexcom, Inc.$181
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,305100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $563 |
| Novo Nordisk | 21 | $450 |
| AstraZeneca | 8 | $232 |
| Sanofi-aventis U.S. LLC | 7 | $193 |
| Pfizer | 11 | $181 |
| Dexcom, Inc. | 5 | $181 |
| Amgen(2 entities) | 10 | $162 |
| Xeris Pharmaceuticals, Inc. | 9 | $159 |
| QOL Medical, LLC | 9 | $138 |
| Ardelyx, Inc. | 6 | $112 |
| GSK | 6 | $110 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $99 |
| IBSA Pharma Inc. | 5 | $99 |
| Lilly USA, LLC | 4 | $70 |
| Corcept Therapeutics | 3 | $64 |
| Exact Sciences | 4 | $61 |
| Abbott | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Radius Health, Inc. | 2 | $32 |
| Bayer | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Phathom Pharmaceuticals, Inc. | 3 | $29 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
| Bridgebio Pharma, Inc. | 1 | $23 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Alkermes, Inc. | 1 | $23 |
| Cvrx, Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Tolmar, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Celltrion USA Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,305 in reported general payments places this provider in the 85th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $71,687 |
| EliquisApixaban | 32 | $42,335 |
| FarxigaDapagliflozin Propanediol | 23 | $35,903 |
| MounjaroTirzepatide | 28 | $33,361 |
| JardianceEmpagliflozin | 22 | $30,986 |
| TradjentaLinagliptin | 12 | $15,493 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $14,412 |
| JanuviaSitagliptin Phosphate | 14 | $10,488 |
| XareltoRivaroxaban | 11 | $10,124 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,809 |
| Atorvastatin Calcium | 250 | $2,237 |
| Duloxetine Hcl | 42 | $1,850 |
| Omeprazole | 90 | $1,533 |
| Levothyroxine Sodium | 134 | $1,461 |
| Gabapentin | 79 | $1,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $450 | $71,68779 claims |
| PfizerEliquis | $181 | $42,33532 claims |
| AstraZenecaFarxiga | $232 | $35,90323 claims |
| Lilly USA, LLCMounjaro | $70 | $33,36128 claims |
| GSKTrelegy Ellipta | $110 | $14,41214 claims |
| MerckJanuvia | $17 | $10,48814 claims |
| AbbVieSynthroid | $563 | $1,30515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 115 primary care providers in South Carolina.
Other primary care in Myrtle Beach
- Kirsten van DemarkMyrtle Beach$2K
- Valencia HenryMyrtle Beach$2K
- Gabrielle JanesMyrtle Beach$1K
- Sarah TomashefskiGreenville$23K
- Samantha VaughtNorth Myrtle Beach$15K
- Cynthia SmithSeneca$10K
- William ByrdSumter$10K
- Kathleen BoonePawleys Island$9K
- Amanda GroomeGreenville$9K
- Holly SurrencyAiken$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.